CanSino Biologics Inc.

SEHK:6185 Voorraadrapport

Marktkapitalisatie: HK$10.4b

CanSino Biologics Beheer

Beheer criteriumcontroles 4/4

De CEO CanSino Biologics is Xuefeng Yu, benoemd in Jan2009, heeft een ambtstermijn van 15.83 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 3.97M, bestaande uit 64.1% salaris en 35.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 11.96% van de aandelen van het bedrijf, ter waarde HK$ 1.25B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.8 jaar en 3.1 jaar.

Belangrijke informatie

Xuefeng Yu

Algemeen directeur

CN¥4.0m

Totale compensatie

Percentage CEO-salaris64.1%
Dienstverband CEO15.8yrs
Eigendom CEO12.0%
Management gemiddelde ambtstermijn6.8yrs
Gemiddelde ambtstermijn bestuur3.1yrs

Recente managementupdates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20
Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20
Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07
The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06
Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13
CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07
Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

May 12
CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Jan 09
Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

Sep 16
CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Aug 31
Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Aug 29
Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13
Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01
Is CanSino Biologics (HKG:6185) Using Too Much Debt?

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15
We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11
CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Analyse CEO-vergoeding

Hoe is Xuefeng Yu's beloning veranderd ten opzichte van CanSino Biologics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-CN¥720m

Jun 30 2024n/an/a

-CN¥867m

Mar 31 2024n/an/a

-CN¥2b

Dec 31 2023CN¥4mCN¥3m

-CN¥1b

Sep 30 2023n/an/a

-CN¥1b

Jun 30 2023n/an/a

-CN¥2b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥5mCN¥2m

-CN¥909m

Compensatie versus markt: De totale vergoeding ($USD 556.77K ) Xuefeng } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 496.15K ).

Compensatie versus inkomsten: De vergoeding van Xuefeng is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Xuefeng Yu (59 yo)

15.8yrs

Tenure

CN¥3,965,000

Compensatie

Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Xuefeng Yu
Co-Founder15.8yrsCN¥3.97m11.96%
HK$ 1.2b
Tao Zhu
Co-Founder15.8yrsCN¥4.42m7.27%
HK$ 757.7m
Dongxu Qiu
Co-Founder15.8yrsCN¥3.74m11.42%
HK$ 1.2b
Shou-Bai Chao
COO, Deputy GM & Executive Director6.5yrsCN¥3.93m0.0081%
HK$ 844.1k
Jing Wang
Chief Commercial Officer3.2yrsCN¥4.57m0.0072%
HK$ 751.4k
Chunlin Xin
Senior Director of New Technology Department7yrsgeen gegevensgeen gegevens
Yonghui Wu
Vice President of Marketingno datageen gegevensgeen gegevens
Jin Cui
Board Secretary5.7yrsgeen gegevensgeen gegevens
Ming King Chiu
Joint Company Secretary5.7yrsgeen gegevensgeen gegevens

6.8yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6185 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Xuefeng Yu
Co-Founder15.8yrsCN¥3.97m11.96%
HK$ 1.2b
Shou-Bai Chao
COO, Deputy GM & Executive Director6.4yrsCN¥3.93m0.0081%
HK$ 844.1k
Jing Wang
Chief Commercial Officer3.1yrsCN¥4.57m0.0072%
HK$ 751.4k
George R. Siber
Co-Chair of Scientific Advisory Board1.8yrsgeen gegevensgeen gegevens
Shuifa Gui
Independent Non-Executive Director5yrsCN¥300.00kgeen gegevens
Luis Barreto
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Zhi Xiao
Chairman of Employee Representative Supervisorless than a yeargeen gegevensgeen gegevens
Jianzhong Liu
Independent Non-Executive Director5yrsCN¥300.00k0.00040%
HK$ 41.7k
Liming Li
Co-Chair of Scientific Advisory Board1.8yrsgeen gegevensgeen gegevens
Jingren Zhang
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Shan Lu
Member of the Scientific Advisory Board2.5yrsgeen gegevensgeen gegevens
Leung Cheung Yiu
Independent Non-Executive Directorno datageen gegevensgeen gegevens

3.1yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6185 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).